Наука и инновации в медицине (Sep 2024)

Organizational features of detection of secondary metachronic primary multiple colorectal cancer in a group of patients with extracolorectal malignancies

  • Vladimir V. Podolskii,
  • Uglesha Stanoevich,
  • Elena A. Podolskaya

DOI
https://doi.org/10.35693/SIM631463
Journal volume & issue
Vol. 9, no. 3
pp. 210 – 215

Abstract

Read online

Aim – to study the organizational features of detection of secondary metachronous primary multiple CRC in patients with primary extracolorectal malignancies. Material and methods. The medical documentation of 163 oncological patients with extracolorectal malignancies and secondary metachronous CRC was analyzed. The patients were divided into subgroups according to the profile of dispensary observation. Results. In 66% (108) of cases, patients were diagnosed with malignancies of four subgroups: skin, breast, urological and gynecological spheres, the number of cases of malignancies’ localization correlated with the number of accumulated contingent. CRC at stage 1 was detected in 24% of cases. The right parts of the colon were affected in 22.1% (36) of cases, the left – in 38.7% (63), the rectum – in 33.1% (54), tumors of several departments – in 4.9% (8), anal cancer – in 1.2% (2) of cases. CRC was detected in the period from 7 to 678 months after extracolorectal malignancies. Earlier, CRC was diagnosed in cases with skin and urological tumors, later, in the group with breast cancer and oncogynecological profile. Conclusion. The majority of the subjects were women (60.7%), the average age was 69 years. Patients with oncodermatological (22%), oncourological (15.3%), oncomammological (15.3%), oncogynecological (13.5%) profiles, lesions of the left colon (38.7%) and rectum (33.1%) predominated. The time interval between the detection of the primary tumor and the detection of secondary CRC depends on the localization of the primary malignancies (p=0).Screening of CRC is necessary not only among the healthy population, but also in the group of patients with extracolorectal malignancies, it is possible to use an immunochemical quantitative stool test for hidden blood at the stage of providing specialized medical care in the "oncology" profile.

Keywords